Blog Big Molecule Watch August 28, 2020

Cadila Pharmaceuticals Announces Launch of Fourth Biosimilar in Two Months

Today, Cadila Pharmaceuticals announced the launch of its adalimumab biosimilar, Cadalimab, in India. HUMIRA® (adalimumab) is approved to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis. Cadila’s press release noted that “[i]n an effort to strengthen their biosimilar product portfolio, Cadalimab is the fourth biosimilar launched in the last 2 months by Cadila Pharmaceuticals.” Cadila has launched 3 other biosimilars in India in the last 2 months, namely Bevaro (bevacizumab), Ritucad (rituximab) and NuPTH (teriparatide) for treatment of cancer and osteoporosis.

The post Cadila Pharmaceuticals Announces Launch of Fourth Biosimilar in Two Months appeared first on Big Molecule Watch.